Alethio Therapeutics

Alethio Therapeutics is a UK-based biotechnology company dedicated to transforming outcomes for patients with chronic blood cancers, specifically myeloproliferative neoplasms (MPNs). The company leverages deep scientific and clinical expertise to develop innovative, disease-modifying biologic therapies, including antibody-drug conjugates (ADCs), that selectively target disease-driving cells. Its efforts are powered by a proprietary discovery and development engine called ARTEMIS.